High density lipoprotein cholesterol: An evolving target of therapy in the management of cardiovascular disease

Navin K. Kapur, Dominique Ashen, Roger S. Blumenthal

Research output: Contribution to journalReview articlepeer-review

Abstract

Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one's risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL's ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)39-57
Number of pages19
JournalVascular health and risk management
Volume4
Issue number1
DOIs
StatePublished - 2008

Keywords

  • Atherosclerosis
  • Coronary
  • High density lipoprotein cholesterol (HDL-C)
  • Reverse cholesterol transport

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'High density lipoprotein cholesterol: An evolving target of therapy in the management of cardiovascular disease'. Together they form a unique fingerprint.

Cite this